Advertisement

Topics

Study of Efficacy and Safety of BCD-217 (Anti-CTLA-4 and Anti-PD-1) Followed By BCD-100 (Anti-PD-1) Versus BCD-100 Monotherapy as First-Line Treatment in Patients With Unresectable or Metastatic Melanoma

2019-04-18 12:14:26 | BioPortfolio

Published on BioPortfolio: 2019-04-18T12:14:26-0400

Clinical Trials [1026 Associated Clinical Trials listed on BioPortfolio]

Melanoma Patients Immunized With Natural DenDritic Cells

The aim of this study is to determine whether adjuvant treatment with nDC vaccination, after complete radical lymph node dissection in stage IIIB and IIIC melanoma patients, improves recur...

Sulindac in Preventing Melanoma in Healthy Participants Who Are at Increased Risk of Melanoma

RATIONALE: Sulindac may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether sulindac is more effective than a placebo in prev...

Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma

The purpose of this clinical research study is to examine the safety and effectiveness (how well the drug works) of two different treatments for patients with melanoma. One treatment is a...

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma

RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. It is not yet known whether combining melanoma vaccine with interleukin-2 is more effective than vaccine...

Health Behaviors, Surveillance, Psychosocial Factors, and Family Concerns

The purpose of this study is to examine the health behaviors of melanoma survivors. We want to know about their thoughts and concerns. Melanoma is a type of skin cancer. The number of peop...

PubMed Articles [1689 Associated PubMed Articles listed on BioPortfolio]

Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF or BRAF mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial.

In the phase 3 COMBI-AD study, patients with resected, stage III melanoma with BRAF or BRAF mutations received adjuvant dabrafenib plus trametinib or placebo. The primary analysis showed that dabrafen...

Melanoma prognosis in the United States: Identifying barriers for improved care.

Despite improvements in melanoma mortality, disparities in melanoma survival persist. We evaluated possible sociodemographic and healthcare-based predictors of differences in U.S. melanoma survival us...

Variation in daily ultraviolet light exposure and sun protection behaviours of melanoma survivors: an observational single-arm pilot study with a wearable sensor.

Melanoma survivors are at risk to develop another melanoma and the same patterns of sun exposure that caused the initial melanoma contribute to the risk for a second melanoma. Despite awareness of the...

Methods of melanoma detection and of skin monitoring for individuals at high risk of melanoma: new Australian clinical practice.

The evidence-based national clinical practice guidelines for the management of cutaneous melanoma published in 2008 are currently being updated. This article summarises the findings from multiple chap...

Epidemiology of melanoma in situ in New Zealand: 2008-2012.

The incidence of melanoma in situ varies throughout the world. It is associated with excellent outcomes, however many of those untreated will go on to develop invasive melanoma with a worse prognosis....

Medical and Biotech [MESH] Definitions

An unpigmented malignant melanoma. It is an anaplastic melanoma consisting of cells derived from melanoblasts but not forming melanin. (Dorland, 27th ed; Stedman, 25th ed)

Experimentally induced tumor that produces MELANIN in animals to provide a model for studying human MELANOMA.

A cellular subtype of malignant melanoma. It is a pigmented lesion composed of melanocytes occurring on sun-exposed skin, usually the face and neck. The melanocytes are commonly multinucleated with a "starburst" appearance. It is considered by many to be the in situ phase of lentigo maligna melanoma.

Found in large amounts in the plasma and urine of patients with malignant melanoma. It is therefore used in the diagnosis of melanoma and for the detection of postoperative metastases. Cysteinyldopa is believed to be formed by the rapid enzymatic hydrolysis of 5-S-glutathionedopa found in melanin-producing cells.

A melanosome-specific protein that plays a role in the expression, stability, trafficking, and processing of GP100 MELANOMA ANTIGEN, which is critical to the formation of Stage II MELANOSOMES. The protein is used as an antigen marker for MELANOMA cells.

More From BioPortfolio on "Study of Efficacy and Safety of BCD-217 (Anti-CTLA-4 and Anti-PD-1) Followed By BCD-100 (Anti-PD-1) Versus BCD-100 Monotherapy as First-Line Treatment in Patients With Unresectable or Metastatic Melanoma"

Advertisement
Quick Search
Advertisement
Advertisement

 

Searches Linking to this Trial